Marketing & Strategy
PRIME Awards 2023 finalists announced
The finalists for PRIME Awards 2023 have been named, with winners to be announced on Thursday the 9th November at the Sofitel Sydney Wentworth.
From the highest number of submissions in the history of PRIME, 55 entries have been successfully shortlisted by a joint panel of 26 judges across marketing, public relations, education, public health, and pharmaceutical sales.
Chair of Judges, David Cousins, said PRIME Awards continues to go from strength to strength with 2023 a record year for entries.
“In this context the commitment from our judges is incredible and I thank them for their ethical, objective, and thorough approach,” said Mr Cousins.
“Even after two rounds of online scoring, the quality of entries this year meant every category was highly competitive, making decisions for our finalist judges extremely challenging. Congratulations to everyone who entered.”
The complete list of finalists can be viewed via the PRIME Awards website. Tickets for the ceremony are now on sale.
PRIME Awards recognises and celebrates excellence within healthcare communications in the pharmaceutical and life sciences industry. Health Industry Hub is the media partner for the event.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More